Clinical studies conducted by IMRA have shown Madeglucyl to be effective in helping to manage both Type I and Type II diabetes; in Type I diabetes, it reportedly reduces (but does not eliminate) daily insulin requirements [9]. The gene discussed is INS; the disease is type 1 diabetes mellitus.